NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, News & Analysis

$296.57
-1.81 (-0.61 %)
(As of 08/20/2019 03:38 PM ET)
Today's Range
$295.18
Now: $296.57
$300.92
50-Day Range
$289.51
MA: $303.12
$318.77
52-Week Range
$287.66
Now: $296.57
$442.00
Volume28,817 shs
Average Volume736,005 shs
Market Capitalization$32.57 billion
P/E Ratio14.98
Dividend YieldN/A
Beta1.15
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.71 billion
Cash Flow$22.1984 per share
Book Value$80.34 per share

Profitability

Net Income$2.44 billion

Miscellaneous

Employees7,400
Market Cap$32.57 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported $5.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $4.60 by $0.69. The biopharmaceutical company earned $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. Regeneron Pharmaceuticals's quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the business earned $5.45 EPS. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Regeneron Pharmaceuticals.

What price target have analysts set for REGN?

17 analysts have issued twelve-month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $325.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $393.3333 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Regeneron’s fourth-quarter results were impressive as the company comfortably beat on both the top and the bottom line. Regeneron’s growth driver, Eylea continues to drive sales, and label expansion of the drug into additional indications has further boosted growth. Dupixent too has boosted performance. The company is working to expand Dupixent’s label further in several other indications. This should diversify the company’s revenue base and reduce dependence on Eylea. In September 2018, the FDA approved its immuno-oncology therapy, Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. New drug approvals boost growth prospects of the company. Shares have outperformed the industry in the past six months. However, the company is highly dependent on Eylea for growth." (2/8/2019)
  • 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral." (11/7/2018)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

News articles about REGN stock have trended positive on Tuesday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Regeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,351,800 shares, a decline of 7.4% from the June 30th total of 2,540,100 shares. Based on an average trading volume of 835,700 shares, the short-interest ratio is currently 2.8 days. Currently, 2.9% of the company's stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Celgene (CELG), Gilead Sciences (GILD), Biogen (biib), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Allergan (AGN) and Alphabet (GOOG).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.56%), BlackRock Inc. (5.53%), Polen Capital Management LLC (1.45%), Invesco Ltd. (1.23%), Northern Trust Corp (0.90%) and Price T Rowe Associates Inc. MD (0.74%). Company insiders that own Regeneron Pharmaceuticals stock include Charles A Baker, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Sustainable Growth Advisers LP, Amundi Pioneer Asset Management Inc., Janus Henderson Group PLC, Janus Henderson Group PLC, Nomura Asset Management Co. Ltd., Wells Fargo & Company MN and NN Investment Partners Holdings N.V.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Parnassus Investments CA, Nuveen Asset Management LLC, Prudential Financial Inc., Renaissance Technologies LLC, Bessemer Group Inc., Marshall Wace LLP and Sumitomo Mitsui Trust Holdings Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $296.19.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $32.53 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,257 (Vote Outperform)
Underperform Votes:  1,063 (Vote Underperform)
Total Votes:  2,320
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel